Progyny (NASDAQ:PGNY) EVP Sells $55,058.08 in Stock

Key Points

• Allison Swartz, the EVP of Progyny, sold 2,398 shares of the company's stock for a total of $55,058.08 at an average price of $22.96, reducing her ownership by 2.92%.
• Progyny reported a quarterly earnings per share (EPS) of $0.19, missing estimates by $0.23, despite a year-over-year revenue increase of 9.5% to $332.87 million.
• Analysts have issued positive ratings for Progyny, with a consensus target price of $25.30, indicating optimism in the company's performance prospects.

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) EVP Allison Swartz sold 2,398 shares of the firm's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the sale, the executive vice president directly owned 79,697 shares of the company's stock, valued at $1,829,843.12. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Allison Swartz also recently made the following trade(s):

• On Thursday, August 28th, Allison Swartz sold 2,398 shares of Progyny stock. The shares were sold at an average price of $22.96, for a total value of $55,058.08.

Progyny Price Performance

Shares of NASDAQ:PGNY traded down $0.26 during trading on Tuesday, hitting $23.41. The company had a trading volume of 740,568 shares, compared to its average volume of 1,396,203. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of 39.68, a price-to-earnings-growth ratio of 1.94 and a beta of 1.33. Progyny, Inc. has a one year low of $13.39 and a one year high of $26.76. The company has a fifty day simple moving average of $22.79 and a two-hundred day simple moving average of $22.21.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.23). The company had revenue of $332.87 million during the quarter, compared to the consensus estimate of $315.70 million. Progyny had a net margin of 4.28% and a return on equity of 10.69%. Progyny's revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.17 earnings per share. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, equities research analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PGNY. Raymond James Financial set a $28.00 price objective on Progyny in a research note on Friday, August 8th. Cantor Fitzgerald restated an "overweight" rating and set a $28.00 price objective (up previously from $26.00) on shares of Progyny in a report on Friday, August 8th. Leerink Partnrs upgraded Progyny from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 8th. Canaccord Genuity Group boosted their price objective on Progyny from $21.00 to $23.00 and gave the company a "hold" rating in a report on Wednesday, August 20th. Finally, Truist Financial boosted their price objective on Progyny from $24.00 to $27.00 and gave the company a "hold" rating in a report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, Progyny has an average rating of "Moderate Buy" and a consensus target price of $25.30.

Institutional Investors Weigh In On Progyny

Institutional investors and hedge funds have recently bought and sold shares of the company. Cetera Trust Company N.A raised its position in Progyny by 303.1% during the 2nd quarter. Cetera Trust Company N.A now owns 1,310 shares of the company's stock valued at $29,000 after purchasing an additional 985 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Progyny during the 1st quarter valued at $44,000. Militia Capital Partners LP raised its position in Progyny by 100.0% during the 1st quarter. Militia Capital Partners LP now owns 2,000 shares of the company's stock valued at $45,000 after purchasing an additional 1,000 shares in the last quarter. Brooklyn Investment Group raised its position in Progyny by 5,216.4% during the 1st quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock valued at $72,000 after purchasing an additional 3,182 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in Progyny during the 2nd quarter valued at $77,000. 94.93% of the stock is owned by institutional investors.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.